Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, I-53100 Siena, Italy.
Curr Top Med Chem. 2010;10(10):1019-35. doi: 10.2174/156802610791293118.
Computational methodologies are used to increase the efficiency of drug discovery process by rendering the design of new drug candidates more rapid and cost-efficient. In silico techniques can be divided in two main groups. Structure-based drug design procedures can be applied (such as docking simulations) if the target is known from experimental (i.e., X-ray crystallographic studies, NMR studies) or theoretical sources (receptor structure built by homology modeling techniques). Otherwise, ligand-based drug design methods can be used (e.g., QSAR or 3D QSAR models, pharmacophoric models) based on the analysis of a number of ligands known to act with a common mechanism of action. Adenosine receptors (ARs) are a family of G-protein coupled receptors (GPCRs) of great interest as targets for therapeutic intervention. Due partly to the lack of reliable adenosine receptor structures, ligand-based drug discovery methods remain the major computational molecular modeling approach applied in the research of new AR ligands. The scope of this review is to summarize the results on pharmacophoric models and 3D QSAR studies concerning AR ligands. In particular, the review will focus on the use of such ligand-based computational techniques for the identification of new AR ligands and/or for their optimization.
计算方法被用于提高药物发现过程的效率,使新候选药物的设计更加快速和具有成本效益。基于结构的药物设计方法可以应用(例如对接模拟),如果目标是从实验(即 X 射线晶体学研究、NMR 研究)或理论来源(通过同源建模技术构建的受体结构)已知的。否则,可以使用基于配体的药物设计方法(例如,QSAR 或 3D QSAR 模型、药效团模型),这些方法基于对已知具有共同作用机制的许多配体的分析。腺苷受体(AR)是 G 蛋白偶联受体(GPCR)家族,作为治疗干预的靶点非常重要。部分由于缺乏可靠的腺苷受体结构,基于配体的药物发现方法仍然是应用于新 AR 配体研究的主要计算分子建模方法。这篇综述的范围是总结关于 AR 配体的药效团模型和 3D QSAR 研究的结果。特别是,该综述将重点介绍此类基于配体的计算技术在识别新的 AR 配体和/或对其进行优化方面的应用。